NEW YORK (GenomeWeb) – AMD Insight today announced it has exclusively licensed from ArcticDx the commercial rights in Canada for the Macula Risk PGx test.

Macula Risk PGx is a prognostic and pharmacogenetic DNA test for evaluating a patient's risk of progressing to advanced age-related macular degeneration and aids in choosing appropriate vitamin formulations for AMD based on the patient's genetic risk profile.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.